Affinage

HSPA12A

Heat shock 70 kDa protein 12A · UniProt O43301

Length
675 aa
Mass
75.0 kDa
Annotated
2026-06-10
20 papers in source corpus 16 papers cited in narrative 16 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

HSPA12A is an atypical HSP70-family protein that acts as a scaffold and trafficking/stability modulator for diverse partner proteins and, in parallel, sustains aerobic glycolysis to drive lactate-dependent signaling and epigenetic programs across multiple cell types (PMID:32332915, PMID:37441587). As a binding protein, it engages partners in an ADP/ATP-dependent manner—first shown for the SorLA cytoplasmic domain, where binding controls SorLA endocytic speed and subcellular localization (PMID:30679749)—and it directs the nuclear translocation of transcriptional and metabolic regulators including PGC-1α in hepatocytes and skeletal muscle (PMID:32332915, PMID:34793778), PKM2 in macrophages (PMID:30455376), and c-Myc in renal tubular cells (PMID:39277835). HSPA12A also governs protein stability through ubiquitin-pathway components: it recruits the HRD1 E3 ligase to drive proteasomal degradation of CD147 (PMID:32754264), and it forms a ternary complex with p53 and USP10 that promotes USP10-mediated deubiquitination and stabilization of p53 (PMID:38219869). A recurrent theme is metabolic control: HSPA12A increases Smurf1-dependent HIF1α protein stability and inhibits GSK3β to sustain glycolytic gene expression and lactate output (PMID:38421727, PMID:39349238, PMID:37580315), and the resulting lactate fuels lactylation of HMGB1, c-Myc, and histone H3 to regulate downstream inflammatory, proliferative, and survival programs (PMID:37441587, PMID:39277835, PMID:38421727). Through these activities HSPA12A controls cell-type-specific outcomes including hepatocyte pyroptosis (PMID:32332915), macrophage M1 polarization (PMID:30455376), adipocyte differentiation via a PPARγ feedback loop (PMID:30742088), cardiac fibroblast activation (PMID:38219869), endothelial barrier integrity and angiogenesis (PMID:34343936, PMID:35783189), and renal tubular cell proliferation (PMID:39277835, PMID:39349238). Its own expression is regulated transcriptionally by PPARγ (PMID:30742088) and post-transcriptionally by SRSF11-mediated exon 2 splicing (PMID:36394206).

Mechanistic history

Synthesis pass · year-by-year structured walk · 16 steps
  1. 2018 High

    Established the first functional link between HSPA12A and metabolic-transcriptional reprogramming by showing it controls nuclear translocation of a partner protein.

    Evidence Co-IP, nuclear fractionation, and Hspa12a-/- mice in macrophages identifying HSPA12A–PKM2 interaction driving M1 polarization in NASH

    PMID:30455376

    Open questions at the time
    • Mechanism by which HSPA12A enhances PKM2 nuclear import not defined
    • Direct binding interface unmapped
  2. 2019 Medium

    Identified the first direct binding partner of HSPA12A and showed binding is nucleotide-dependent, framing it as an HSP70-like scaffold acting on cargo trafficking.

    Evidence Reciprocal Co-IP/pulldown with ADP/ATP-dependent binding assays and SorLA acidic-residue mutagenesis, plus endocytosis assays

    PMID:30679749

    Open questions at the time
    • No independent replication
    • Selectivity for SorLA over Sortilin mechanistically unexplained
    • No structural model of the interaction
  3. 2019 High

    Placed HSPA12A within a transcriptional feedback circuit by establishing both that PPARγ directly drives its expression and that it is required for adipogenesis.

    Evidence ChIP for PPARγ binding to the Hspa12a promoter, Hspa12a-/- mice, and GW9662 pharmacological rescue in primary adipocyte precursors

    PMID:30742088

    Open questions at the time
    • Molecular mechanism by which HSPA12A promotes PPARγ expression unresolved
  4. 2020 High

    Demonstrated HSPA12A directly binds PGC-1α and routes it to the nucleus to suppress hepatocyte pyroptosis, generalizing the nuclear-translocation scaffold model to a protective metabolic regulator.

    Evidence Reciprocal Co-IP, Hspa12a-/- mice, and AOAH overexpression rescue measuring Caspase-11/GSDMD cleavage in sepsis liver injury

    PMID:32332915

    Open questions at the time
    • Binding interface and nucleotide dependence of the PGC-1α interaction not mapped
  5. 2020 High

    Extended HSPA12A function to ubiquitin-proteasome control of a substrate by showing it recruits an E3 ligase to degrade a glycolytic transporter.

    Evidence MS interactome, Co-IP for HSPA12A–HRD1, cycloheximide/MG132 stability assays, and CD147 rescue in renal cell carcinoma

    PMID:32754264

    Open questions at the time
    • Whether HSPA12A is a co-factor versus adaptor for HRD1 unclear
    • Direct CD147 contact not demonstrated
  6. 2021 Medium

    Linked HSPA12A to endothelial protective kinase signaling, showing it preserves barrier integrity through ERK/Akt activation.

    Evidence HUVEC overexpression, Hspa12a-/- LPS-ALI mice, and ERK/Akt inhibitor rescue with permeability and VE-cadherin/VEGF readouts

    PMID:34343936

    Open questions at the time
    • How HSPA12A activates ERK/Akt is unknown
    • No direct upstream effector identified
  7. 2021 Medium

    Connected HSPA12A to PGC-1α-dependent mitochondrial integrity in skeletal muscle, positioning it upstream of mitochondrial protection.

    Evidence C2C12 overexpression, SR-18292 PGC-1α inhibitor rescue, mitochondrial morphology/ATP assays, and bupivacaine in vivo model

    PMID:34793778

    Open questions at the time
    • No direct HSPA12A–PGC1α binding shown in this study
    • Mechanism of PGC1α nuclear retention unaddressed
  8. 2022 Medium

    Showed HSPA12A drives angiogenesis through p38/ERK→AP-1 signaling and pro-angiogenic gene expression.

    Evidence Endothelial gain/loss-of-function, Hspa12a-/- MI mice, p38/ERK inhibitor rescue, nuclear fractionation, and tube-formation assays

    PMID:35783189

    Open questions at the time
    • Direct molecular trigger of MAPK activation by HSPA12A unknown
  9. 2022 Medium

    Revealed post-transcriptional control of HSPA12A itself, with an exon-2-retaining isoform that stabilizes N-cadherin mRNA in colorectal cancer.

    Evidence CLIP for SRSF11 binding, mini-gene splicing reporter, RNA-seq, in vitro PAK5 kinase assay, and RNA stability assays

    PMID:36394206

    Open questions at the time
    • Functional difference between isoforms at protein level not dissected
    • Single lab
  10. 2023 High

    Defined the glycolysis→lactate→protein lactylation axis as a core HSPA12A output, with hepatocyte HSPA12A limiting HMGB1 lactylation and macrophage recruitment.

    Evidence Hepatocyte-specific overexpression and Hspa12a-/- mice, HMGB1 lactylation Co-IP, HMGB1 knockdown rescue, and chemotaxis assays in liver I/R

    PMID:37441587

    Open questions at the time
    • How HSPA12A lowers hepatocyte glycolysis molecularly not fully resolved
  11. 2023 Medium

    Established HSPA12A as a regulator of cerebral lactate homeostasis via GSK3β inhibition, linking its metabolic role to neurogenesis and behavior.

    Evidence Hspa12a-/- behavioral tests, BrdU neurogenesis, CSF lactate measurement, neuronal overexpression, and lactate rescue administration

    PMID:37580315

    Open questions at the time
    • GSK3β inhibition mechanism less directly validated
    • Direct HSPA12A–GSK3β interaction not shown
  12. 2024 High

    Demonstrated a scaffolding function in protein stabilization by showing HSPA12A bridges p53 and USP10 to promote p53 deubiquitination and limit cardiac fibrosis.

    Evidence Co-IP of HSPA12A–p53 and HSPA12A–USP10, cycloheximide/MG132 stability assays, Hspa12a-/- MI mice, and fibrosis staining

    PMID:38219869

    Open questions at the time
    • Stoichiometry and binding interfaces of the ternary complex unresolved
  13. 2024 Medium

    Connected HSPA12A to HIF1α-driven glycolysis and histone H3 lactylation supporting cardiomyocyte survival after reperfusion.

    Evidence Hspa12a-/- MI/R mice, cardiomyocyte gain/loss-of-function, glycolytic flux, H3 lactylation assay, and Smurf1-dependent HIF1α stability analysis

    PMID:38421727

    Open questions at the time
    • Direct HSPA12A–Smurf1 interaction evidence limited
    • How HSPA12A modulates Smurf1 activity unknown
  14. 2024 Medium

    Showed HSPA12A both binds c-Myc to enhance its nuclear localization and amplifies c-Myc lactylation through HIF1α-dependent lactate, driving renal tubular proliferation.

    Evidence Co-IP for HSPA12A–c-Myc, c-Myc lactylation assay with inhibitor rescue, nuclear fractionation, and Hspa12a-/- KI/R model

    PMID:39277835

    Open questions at the time
    • Relative contribution of direct binding versus lactylation to nuclear c-Myc unclear
  15. 2024 Medium

    Dissected the Smurf1→HIF1α→glycolysis pathway in renal tubular cells, distinguishing HIF1α protein stabilization from transcription.

    Evidence HK-2 gain/loss-of-function, YC-1 HIF1α inhibitor, cycloheximide stability assays, qPCR, and glycolysis inhibitors after hypoxia/reoxygenation

    PMID:39349238

    Open questions at the time
    • In vitro only
    • Direct HSPA12A–Smurf1 binding not demonstrated
  16. 2024 Medium

    Identified an mTOR-autophagy axis through which HSPA12A promotes TLR4/NF-κB inflammation in septic cardiomyopathy, contrasting with its protective roles elsewhere.

    Evidence Hspa12a-/- CLP sepsis mice, cardiomyocyte overexpression, rapamycin rescue, LC3-II/p62 and NF-κB immunoblotting, and death staining

    PMID:39642573

    Open questions at the time
    • How HSPA12A activates mTOR is unknown
    • Cell-type basis of protective-versus-deleterious outcomes unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown whether HSPA12A possesses intrinsic chaperone/ATPase activity and how a single protein achieves context-dependent partner selectivity across trafficking, ubiquitin-pathway, and glycolytic functions.
  • No structural model or domain-level dissection
  • Nucleotide-dependence shown only for SorLA binding
  • No unified rule for partner selection across cell types

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0098772 molecular function regulator activity 4 GO:0060090 molecular adaptor activity 3 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005829 cytosol 3
Pathway
R-HSA-1430728 Metabolism 4 R-HSA-168256 Immune System 3 R-HSA-162582 Signal Transduction 2 R-HSA-392499 Metabolism of proteins 2
Partners
HRD1MYCPGC1APKM2SORL1SRSF11TP53USP10

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 HSPA12A selectively binds to the cytoplasmic domain of SorLA (but not Sortilin) in an ADP/ATP-dependent manner, mediated by specific acidic residues in SorLA's cytosolic domain, and this interaction affects both endocytic speed and subcellular localization of SorLA. This is the first described substrate/binding partner of HSPA12A. Co-immunoprecipitation/pulldown, ADP/ATP-dependent binding assay, site-directed mutagenesis of SorLA acidic residues, subcellular localization assay, endocytosis assay Scientific reports Medium 30679749
2020 HSPA12A directly interacts with PGC-1α in hepatocytes and increases its nuclear translocation, thereby inducing AOAH (acyloxyacyl hydrolase) expression, which inactivates cytosolic LPS and inhibits Caspase-11-mediated gasdermin D cleavage (pyroptosis) during sepsis-induced liver injury. Immunoprecipitation (direct protein interaction), loss- and gain-of-function studies (Hspa12a-/- mice and overexpression), immunoblotting for Caspase-11 and GSDMD cleavage, AOAH overexpression rescue experiment Cell death and differentiation High 32332915
2018 HSPA12A interacts with the M2 isoform of pyruvate kinase (PKM2) in macrophages and promotes its nuclear translocation, thereby driving M1 macrophage polarization and secretion of pro-inflammatory cytokines, which in turn cause hepatocyte steatosis via paracrine effects in NASH. Immunoprecipitation (HSPA12A–PKM2 interaction), loss- and gain-of-function in macrophages, nuclear fractionation, Hspa12a-/- mice on high-fat diet, paracrine co-culture assays Diabetes High 30455376
2019 HSPA12A is required for adipocyte differentiation through a positive feedback loop with PPARγ: PPARγ directly binds the PPAR response element in the Hspa12a promoter (confirmed by ChIP), activating HSPA12A expression, while HSPA12A in turn promotes PPARγ expression and adipogenic gene transcription during differentiation. Chromatin immunoprecipitation (ChIP) for PPARγ binding to Hspa12a promoter, Hspa12a-/- mouse model (high-fat diet), PPARγ inhibitor (GW9662) rescue, loss- and gain-of-function in primary adipocyte precursors Cell death and differentiation High 30742088
2020 HSPA12A in renal cell carcinoma (RCC) cells interacts with HRD1 ubiquitin E3 ligase and promotes ubiquitin-proteasome degradation of CD147, thereby reducing lactate export and glycolysis, and suppressing RCC cell migration. CD147 overexpression abolishes HSPA12A's inhibitory effects on lactate export and migration. Mass spectrometry (interactome), immunoprecipitation (HSPA12A–HRD1 interaction), cycloheximide chase and MG132 proteasome inhibitor assays (protein stability), CD147 overexpression rescue, Transwell migration and wound healing assays, Seahorse glycolysis assay Theranostics High 32754264
2021 HSPA12A overexpression in endothelial cells protects against LPS-induced endothelial hyperpermeability and death by activating ERKs and Akt phosphorylation; pharmacological inhibition of either ERKs or Akt abolished HSPA12A's protective effects. HSPA12A also upregulated VE-cadherin and downregulated VEGF expression. HSPA12A overexpression in HUVECs, Hspa12a-/- mouse model (LPS-induced ALI), ERK/Akt inhibitor treatment, immunoblotting for phosphorylation, permeability assay, cell death assay International immunopharmacology Medium 34343936
2022 HSPA12A promotes angiogenesis in endothelial cells by activating p38 and ERK phosphorylation, leading to increased AP-1 phosphorylation and nuclear localization, which drives expression of VEGF, VEGFR2, and Ang-1. Inhibition of p38 or ERKs abolished HSPA12A-promoted AP-1 activation and angiogenic characteristics. HSPA12A overexpression/deficiency in endothelial cells, Hspa12a-/- mouse MI model, p38/ERK inhibitor pharmacological rescue, immunoblotting for phosphorylation, nuclear fractionation, tube formation/migration/proliferation assays, echocardiography Oxidative medicine and cellular longevity Medium 35783189
2022 SRSF11 directly binds a motif in exon 2 of HSPA12A pre-mRNA (confirmed by CLIP and mini-gene assay) and promotes exon 2 skipping; the HSPA12A transcript retaining exon 2 increases N-cadherin expression by enhancing RNA stability, thereby promoting colorectal cancer metastasis. PAK5 phosphorylates SRSF11 at serine 287 to protect it from ubiquitination, maintaining SRSF11-mediated HSPA12A splicing regulation. UV crosslinking and immunoprecipitation (CLIP), mini-gene reporter assay, RNA-seq, in vitro kinase assay (PAK5 phosphorylates SRSF11), Co-IP, Phospho-tag SDS-PAGE, RNA stability assay Clinical and translational medicine Medium 36394206
2023 Hepatocyte HSPA12A overexpression reduces glycolysis-generated lactate, thereby decreasing HMGB1 lactylation and secretion from hepatocytes during liver ischemia/reperfusion (LI/R); HMGB1 knockdown reversed the deleterious effects of HSPA12A knockout on macrophage chemotaxis and inflammatory activation, placing HSPA12A upstream of glycolysis → lactate → HMGB1 lactylation → macrophage recruitment in LI/R injury. Hepatocyte-specific HSPA12A overexpression (in vivo), Hspa12a-/- mice, HMGB1 knockdown rescue, immunoprecipitation for HMGB1 lactylation, Transwell chemotaxis assay, exosome HMGB1 quantification, ALT/AST assays Theranostics High 37441587
2023 HSPA12A in hippocampal neurons inhibits GSK3β to sustain glycolytic enzyme expression and lactate production; Hspa12a-/- mice show decreased CSF lactate, impaired adult hippocampal neurogenesis, and mood instability behaviors, all of which are rescued by lactate administration, establishing HSPA12A as a regulator of cerebral lactate homeostasis via GSK3β inhibition. Hspa12a-/- mouse behavioral tests (open field, forced swimming, elevated plus maze, sucrose preference), BrdU neurogenesis labeling, CSF lactate measurement, HSPA12A overexpression in primary hippocampal neurons (glycolysis readout), lactate rescue administration Translational psychiatry Medium 37580315
2024 HSPA12A acts as a scaffolding protein in cardiac fibroblasts by binding both p53 and USP10 (ubiquitin-specific protease 10) simultaneously, thereby promoting USP10-mediated deubiquitination and stabilization of p53 protein, which in turn inhibits glycolysis and prevents cardiac fibroblast activation into myofibroblasts; Hspa12a-/- mice showed exacerbated cardiac fibrosis post-MI. Immunoprecipitation-immunoblotting (HSPA12A–p53 and HSPA12A–USP10 interactions), cycloheximide and MG132 stability assays, Hspa12a-/- mouse MI model, Masson/picrosirius staining for fibrosis, echocardiography, primary cardiac fibroblast loss/gain-of-function Journal of advanced research High 38219869
2024 In cardiomyocytes, HSPA12A maintains aerobic glycolysis during reperfusion by increasing Smurf1-mediated HIF1α protein stability, which upregulates glycolytic gene expression and sustains H3 (Histone 3) lactylation as an epigenetic mechanism supporting cardiomyocyte survival; Hspa12a-/- mice showed exacerbated aerobic glycolysis decrease and worse MI/R injury. Hspa12a-/- mouse MI/R model, gain- and loss-of-function in cardiomyocytes, glycolytic flux measurement, H3 lactylation assay (epigenetic readout), HIF1α protein stability assay, Smurf1-dependent mechanism analysis, echocardiography JCI insight Medium 38421727
2024 HSPA12A directly interacts with c-Myc in renal tubular epithelial cells and enhances its nuclear localization; HSPA12A also promotes glycolysis-derived lactate generation in a HIF1α-dependent manner, increasing c-Myc lactylation, which further enhances c-Myc nuclear localization and transcription of proliferation-related genes to support TEC proliferation after KI/R; inhibiting c-Myc lactylation abolished HSPA12A-induced proliferation. Co-immunoprecipitation (HSPA12A–c-Myc direct interaction), c-Myc lactylation assay, pharmacological inhibition of c-Myc lactylation, nuclear fractionation, gain-of-function HSPA12A overexpression, HIF1α-dependent mechanism analysis, Hspa12a-/- mouse KI/R model Cellular and molecular life sciences : CMLS Medium 39277835
2024 In cardiomyocytes during sepsis, HSPA12A overexpression activates mTOR and inhibits autophagy, thereby enhancing TLR4/MyD88/NF-κB-mediated inflammation; conversely, HSPA12A knockout attenuated sepsis-induced cardiomyocyte death and cardiac dysfunction. Rapamycin (mTOR inhibitor) abolished the HSPA12A-induced autophagy inhibition and inflammation, placing HSPA12A upstream of mTOR-autophagy in the septic cardiomyopathy pathway. Hspa12a-/- mouse CLP sepsis model, HSPA12A overexpression in primary cardiomyocytes, rapamycin pharmacological rescue, LC3-II/p62 autophagy markers, NF-κB pathway immunoblotting, TUNEL/PI death staining, echocardiography International immunopharmacology Medium 39642573
2021 HSPA12A downregulation during bupivacaine-induced myotoxicity underlies mitochondrial damage in skeletal muscle; HSPA12A overexpression attenuated bupivacaine-induced cell death, restored glucose consumption and ATP production, reduced mitochondrial fragmentation, and maintained PGC1α expression and nuclear localization. Pharmacological inhibition of PGC1α (SR-18292) abolished HSPA12A-mediated protection, placing HSPA12A upstream of PGC1α-mediated mitochondrial integrity. HSPA12A overexpression in C2C12 myoblasts, PGC1α inhibitor (SR-18292) rescue, mitochondrial content and morphology assay, ATP production assay, PGC1α nuclear fractionation, Bupivacaine in vivo mouse model Toxicology and applied pharmacology Medium 34793778
2024 HSPA12A promotes HIF1α protein stability through a Smurf1-dependent mechanism in renal tubular epithelial cells (HK-2) after hypoxia/reoxygenation, independently of HIF1α transcription; HIF1α pharmacological inhibition (YC-1) abolished HSPA12A-promoted glycolytic flux and cell proliferation, confirming HSPA12A acts through Smurf1→HIF1α→glycolysis to support TEC proliferation. HSPA12A gain- and loss-of-function in HK-2 cells, HIF1α inhibitor (YC-1), cycloheximide protein stability assay, qPCR (HIF1α transcription vs. protein), glycolysis inhibitors (2-DG, oxamate), proliferation assay Cell stress & chaperones Medium 39349238

Source papers

Stage 0 corpus · 20 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. International journal of medical sciences 149 25798051
2023 Hepatocyte HSPA12A inhibits macrophage chemotaxis and activation to attenuate liver ischemia/reperfusion injury via suppressing glycolysis-mediated HMGB1 lactylation and secretion of hepatocytes. Theranostics 126 37441587
2020 HSPA12A attenuates lipopolysaccharide-induced liver injury through inhibiting caspase-11-mediated hepatocyte pyroptosis via PGC-1α-dependent acyloxyacyl hydrolase expression. Cell death and differentiation 87 32332915
2018 HSPA12A Is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-Mediated M1 Macrophage Polarization. Diabetes 66 30455376
2024 HSPA12A maintains aerobic glycolytic homeostasis and Histone3 lactylation in cardiomyocytes to attenuate myocardial ischemia/reperfusion injury. JCI insight 49 38421727
2019 HSPA12A is required for adipocyte differentiation and diet-induced obesity through a positive feedback regulation with PPARγ. Cell death and differentiation 38 30742088
2020 HSPA12A unstabilizes CD147 to inhibit lactate export and migration in human renal cell carcinoma. Theranostics 30 32754264
2013 The response profiles of HSPA12A and TCTP from Mytilus galloprovincialis to pathogen and cadmium challenge. Fish & shellfish immunology 24 23643947
2024 HSPA12A acts as a scaffolding protein to inhibit cardiac fibroblast activation and cardiac fibrosis. Journal of advanced research 21 38219869
2024 HSPA12A promotes c-Myc lactylation-mediated proliferation of tubular epithelial cells to facilitate renal functional recovery from kidney ischemia/reperfusion injury. Cellular and molecular life sciences : CMLS 19 39277835
2022 Alternative splicing of HSPA12A pre-RNA by SRSF11 contributes to metastasis potential of colorectal cancer. Clinical and translational medicine 19 36394206
2015 Polymorphisms of PRLHR and HSPA12A and risk of gastric and colorectal cancer in the Chinese Han population. BMC gastroenterology 15 26302849
2021 HSPA12A improves endothelial integrity to attenuate lung injury during endotoxemia through activating ERKs and Akt-dependent signaling. International immunopharmacology 14 34343936
2023 HSPA12A controls cerebral lactate homeostasis to maintain hippocampal neurogenesis and mood stabilization. Translational psychiatry 12 37580315
2019 HSPA12A targets the cytoplasmic domain and affects the trafficking of the Amyloid Precursor Protein receptor SorLA. Scientific reports 11 30679749
2022 HSPA12A Stimulates p38/ERK-AP-1 Signaling to Promote Angiogenesis and Is Required for Functional Recovery Postmyocardial Infarction. Oxidative medicine and cellular longevity 10 35783189
2024 Downregulation of HSPA12A protects heart against sepsis through suppressing mTOR-mediated inflammatory response in cardiomyocytes. International immunopharmacology 7 39642573
2024 HSPA12A stimulates "Smurf1-Hif1α-aerobic glycolysis" axis to promote proliferation of renal tubular epithelial cells after hypoxia/reoxygenation injury. Cell stress & chaperones 2 39349238
2023 HSPA12A was identified as a key driver in colorectal cancer GWAS loci 10q26.12 and modulated by an enhancer-promoter interaction. Archives of toxicology 2 37245169
2021 Downregulation of HSPA12A underlies myotoxicity of local anesthetic agent bupivacaine through inhibiting PGC1α-mediated mitochondrial integrity. Toxicology and applied pharmacology 0 34793778

Missed literature

Know a paper Affinage missed for HSPA12A? Flag it for the maintainers and the community.

No submissions yet.